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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
We aim to review and synthesise evidence from randomised controlled trials of hormonal and non-hormonal treatments in women
with catamenial epilepsy. The primary objectives are to evaluate the efficacy and safety of hormonal and non-hormonal treatments for
catamenial seizures.
B A C K G R O U N D
Description of the condition
Studies have shown that in developed countries, prevalence rates
for active epilepsy are between 4 and 10 per 1000 (Sander 1996).
In a systematic review of incidence studies, the median annual
incidence of epilepsy was 50.7 per 100,000 for males and 46.2
per 100,000 for females (Kotsopoulos 2002). Globally, 50% of
women and girls with epilepsy are in the reproductive age range
of 15 to 49 years.
Catamenial epilepsy describes a worsening of seizures in relation to
the menstrual cycle (peri-menstrual seizures); it may affect around
40% of women with epilepsy (Herzog 1997). Studies examining
day-to-day comparisons of seizures throughout the menstrual cy-
cle have consistently shown a greater likelihood of seizures on day
one (the start of menstruation), with the lowest risk of seizures on
day 20 (the mid-luteal phase) (Laidlaw 1956; Rosciszewska 1980;
Ansell 1986; Tauboll 1991; Herzog 1997). The menstrual cycle is
characterised by two phases: the follicular phase (day one to day
13), which comprises menstruation (day one to five) followed by
ovulation (day 14), and the luteal phase (day 15 to 28). There are
two major hormonal changes: a preovulatory surge in oestradiol
(day 10 to 15), and a premenstrual drop in progesterone levels (day
25 to 28). In one study of 184 women with focal epilepsy, there
was statistically significant evidence for greater seizure occurrences
around the time of these two critical hormonal changes, compared
with the mid-follicular and mid-luteal phases. These time periods
were categorised as catamenial type 1 (C1) pattern (day -3 (25) to
day 3) and catamenial type 2 (C2) pattern (day 10 to 15). A third
pattern - catamenial type 3 (C3) - was noted in patients experi-
encing anovulatory cycles (where no ovulation occurs during the
cycle), whereby a lack of progesterone secretion during the luteal
phase predisposed to a higher mid-luteal ratio of oestradiol to pro-
gesterone, which placed the patient at risk of seizures throughout
the luteal phase (Herzog 1997). The hormonal changes and cata-
menial seizure patterns during a menstrual cycle are summarised
in Figure 1.
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Figure 1. Figure 1: Hormonal changes and catamenial seizures patterns during the menstrual cycle
Approximately 10% of menstrual cycles in healthy women are
anovulatory, whereas 35% are anovulatory in women with tem-
poral lobe epilepsy (Herzog 2001). In a study conducted in 1997,
around 42% of women demonstrated at least one of the three
patterns of catamenial epilepsy. Around 36% had C1 pattern,
29% had C2 pattern, and 42% had C3 pattern (Herzog 1997).
Other studies have reported higher prevalence rates (between
63% and 78%), however they compared seizures in just peri-
menstrual phases versus other phases of the cycle (Laidlaw 1956;
Rosciszewska 1980; Ansell 1986; Tauboll 1991). When a simi-
lar comparison was made in the 1997 study, a prevalence rate of
71% was found (Herzog 1997). Reported clinical risk factors for
catamenial epilepsy are: younger age, temporal lobe seizures and
a left-sided epileptogenic foci, which implies that cyclical seizure
rhythms are affected by the neuroanatomic substrate of the seizure
focus (Quigg 2009).
Description of the intervention
In patients with catamenial seizures, non-hormonal and hormonal
treatments may be considered in addition to regular medication.
Non-hormonal treatments include pulsed clobazam and acetazo-
lamide. Hormonal treatments include natural progesterone sup-
plements, synthetic oral or intramuscular progesterones, allopreg-
nanolone, and gonadotropin-releasing hormone (GnRH) ana-
logues (triptorelin and goserelin).
For women with catamenial epilepsy who have regular menstrual
cycles, intermittent treatment approaches are considered. These
interventions target vulnerable days of the menstrual cycle peri-
menstrually (C1 pattern), at ovulation (C2 pattern), and during
the luteal phase (C3 pattern). TheNIHprogesterone trial (Herzog
2012) assigned 462 women with drug-resistant seizures to either
oral progesterone or placebo taken during days 14 to 28, and ob-
served changes in seizure frequency (a reduction of more than
50%) between the three-month baseline and three-month treat-
ment period. The study found comparable outcomes for proges-
terone and placebo overall. However, a secondary analysis iden-
tified that the women most likely to respond were those with a
C1 pattern seizure type (secondary generalised seizures and fo-
cal seizures with altered awareness) and a threefold higher peri-
menstrual seizure frequency. The study demonstrated a favourable
short-term safety profile (Herzog 2012). However, the study did
not showa clear effect inwomenwithC2orC3pattern,whichmay
reflect differences in underlying pathophysiology. Other intermit-
tent cyclic treatments include benzodiazepines, acetazolamide, or
increasing the dose of an anti-seizure drug already in use.
For women with irregular menstrual cycles, or in those for whom
the intermittent cyclic treatments are not effective, the option of
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pharmacologically stopping the menstrual cycle altogether may be
considered, either by using synthetic hormones such as medrox-
yprogesterone (Depo-Provera), GnRH analogues (triptorelin and
goserelin), or sustained oral contraceptives.
How the intervention might work
Preclinical studies have demonstrated that withdrawal of proges-
terone or its reduced metabolite allopregnanolone, as occurs pre-
menstrually, can cause insensitivity to the inhibitory neurotrans-
mitter gamma-Aminobutyric acid (GABA) and also to benzo-
diazepines that act to enhance GABA transmission (Gangisetty
2010). This is thought to occur by the alteration in the subunit
composition of the GABA-A receptor (Maguire 2005). In animal
models, progesterone has been found to reduce neuronal firing
and decrease spontaneous and induced epileptiform discharges
(Reddy 2004). Progesterone has demonstrated effects on reduc-
ing the number of excitatory synapses and the number of oestro-
gen receptors (McEwan 2001). Other experimental studies sup-
port the role of allopregnanolone (a metabolite of progesterone) as
conferring seizure protection, with the role of progesterone largely
unexplained (Kokate 1999).
The mechanism by which oestradiol causes seizures is uncertain
(Osbourne 2009). It may regulate the limbic system; there is evi-
dence of oestradiol synthesising enzymes present within the hip-
pocampus of the temporal lobe. It has also been hypothesised that
oestradiol increases excitation by enhancing glutamate transmis-
sion and associated receptors (Woolley 1994; Smejkalova 2010).
Several studies of chronic oestrogen administration in females,
however, show either anticonvulsant effects or no effect of oestro-
gen on seizures. Studies have also demonstrated that, in low doses,
oestradiol can produce neuro-protective effects (Velísková 2000;
Kalkbrenner 2003). Modulation of enzymes involved in gluta-
mate breakdown to GABA have been proposed as neuroprotective
mechanisms (Joh 2006; Ledoux 2009).
A detailed understanding of the patterns and pathophysiology is
paramount for the development of rational approaches for pre-
venting and treating catamenial epilepsy.
Why it is important to do this review
Catamenial epilepsy and seizure exacerbation is common in
women with epilepsy, and may have a significant negative impact
on quality of life. Patients may not be receiving appropriate treat-
ment for their catamenial seizures because of uncertainty regard-
ing which treatment works best and when in the menstrual cycle
treatment should be taken, as well as the possible impact on fer-
tility, the menstrual cycle, bone health and cardiovascular health.
This review aims to address these issues and inform clinical prac-
tice and future research.
O B J E C T I V E S
We aim to review and synthesise evidence from randomised con-
trolled trials of hormonal and non-hormonal treatments inwomen
with catamenial epilepsy. The primary objectives are to evaluate
the efficacy and safety of hormonal and non-hormonal treatments
for catamenial seizures.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised and quasi-randomised controlled
studies of blinded or open-label design. We will only include
studies which randomise participants individually (i.e. cluster-ran-
domised trials will not be included). We will include trials with a
cross-over design if each treatment period was at least 12 weeks in
length and the trial had a suitable washout period.
Types of participants
We will include women of childbearing age who have experienced
a catamenial pattern of seizures in at least two baseline cycles,
defined as one or more of the following.
1. C1 pattern: a greater average daily seizure frequency during
the peri-menstrual phase (days -3 to +3) compared with the mid-
follicular phase (days 4 to 9) and mid-luteal phase (days -12 to
14) in normal ovulatory cycles.
2. C2 pattern: a greater average daily seizure frequency during
the peri-ovulatory phase (days 10- to -13) compared to the mid-
follicular phase (days 4 to 9) and mid-luteal phase (days -12 to
14) in normal ovulatory cycles.
3. C3 pattern: a greater average daily seizure frequency during
the luteal phase (days 15 to 28) compared to the follicular phase
(days 1 to 14) in anovulatory cycles.
Types of interventions
We will include the following intervention and control groups.
Intervention group: women who received a hormonal or non-hor-
monal drug intervention, in addition to an existing antiepileptic
drug regimen for a minimum treatment duration of 12 weeks.
Control group(s): women who received a placebo, comparative
drug intervention, or no treatment, in addition to an existing
antiepileptic drug regimen for a minimum treatment duration of
12 weeks.
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Types of outcome measures
Primary outcomes
1. Seizure freedom, defined as the proportion of women who
become seizure-free over the treatment period.
2. Responder rate, defined as the proportion of women with a
50% reduction in seizure frequency compared to baseline.
3. Change in seizure frequency, defined as the absolute and
percentage change in seizure frequency compared to baseline.
Secondary outcomes
1. Withdrawals, defined as the number of withdrawals from
allocated treatment or from the trial.
i) Withdrawals for any reason
ii) Withdrawals due to lack of efficacy
iii) Withdrawals due to adverse events
2. Adverse events: of interest (outlined below), including
serious adverse events; and other events reported in the trials




iv) Osteoporosis and bone health
v) Mood disorders
vi) Sedation
vii) Menstrual cycle disorders
viii) Fertility issues
3. Quality of life, according to validated general scales such as
the 36-Item Short Form Health Survey (SF-36), EuroQol 5-
Dimensions (EQ-5D) or epilepsy-specific scales such as the
Quality Of Life In Epilepsy -31 (QOLIE-31).
i) Total quality-of-life score
ii) Domain-specific scores of quality-of-life scales
In the first instance, we intend to report change from baseline in
quality of life. If change-from-baseline scores are not available, we
will report the final scores.
Search methods for identification of studies
Electronic searches
We will search the following databases, with no language restric-
tions. We will seek translation of reports published in any lan-
guages other than English.
1. Cochrane Epilepsy Group Specialized Register
2. Cochrane Central Register of Controlled Trials
(CENTRAL), via the Cochrane Register of Studies Online
(CRSO)
3. MEDLINE (Ovid) 1946 to present date
4. ClinicalTrials.gov
5. WHO International Clinical Trials Registry Platform
(ICTRP)
The proposed search strategy forMEDLINE is set out inAppendix
1. This strategy will be modified for use with the other databases.
Searching other resources
We will review the reference lists of retrieved trials to check for
additional reports of relevant studies.
Data collection and analysis
Selection of studies
The two review authors (MM and SJN) will independently assess
trials for inclusion using the Cochrane Covidence software. Firstly
we will screen the titles and abstracts of the records, and exclude
any that are clearly irrelevant. Subsequently, full-text articles will
be screened for inclusion and any found not to be eligible will be
excluded, and the reason for exclusion will be recorded. Any dis-
agreements between the authors regarding eligibility of trials will
be resolved by discussion. The screening process will be displayed
in a PRISMA study flow diagram (Moher 2009).
Data extraction and management
We will extract the following information for each trial, using a
data extraction form.
Methodology/trial design
1. Method of randomisation and concealment
2. Method of blinding
3. Trial inclusion and exclusion criteria
4. Number of people excluded from analyses
5. Duration of trial periods, e.g. baseline, treatment, and
follow-up periods, and total trial duration
6. Trial intervention treatment: type of drug and dose
7. Trial control treatment: type of control (including type of
drug and dose if applicable)
8. Source of funding of the trial and author disclosures
Participant demographics
1. Total number of women randomised to each group
2. Age (overall and by treatment group)
3. Epilepsy/seizure type
4. Epilepsy duration and aetiology
5. Existing anti-epileptic drug regimen (including dose,
overall and by treatment group)
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6. Baseline seizure frequency (overall and by treatment group)
7. Proportion with C1, C2 and C3 catamenial pattern of
seizures
Results
1. Number of women included in analysis of each outcome by
treatment group
2. Outcome summary data for each intervention (see Types of
outcome measures)
The two review authors (MM and SJN) will independently ex-
tract data for each trial and compare extractions. We will pilot the
content of the form on an eligible trial and add to the content if
required. Any discrepancies in data extracted by the two review
authors will be resolved by discussion.
If any of the above information appears to have been recorded but
not published within the trial reports, or if information is unclear,
we will attempt to contact original trial authors for clarification.
Assessment of risk of bias in included studies
The two review authors (MM and SJN) will independently assess
the risk of bias for each trial using the Cochrane ’Risk of bias’ tool,
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We will rate each of the following
six domains as low, unclear or high risk of bias: method of generat-
ing random sequence, allocation concealment, blinding methods,
incomplete outcome data, selective outcome reporting and other
sources of bias. Any discrepancies in the ’Risk of bias’ judgements
of the two review authors will be resolved by discussion.
Measures of treatment effect
Wewill report dichotomous data (seizure freedom, responder rate,
withdrawals and adverse events) as risk ratios (RRs) with 95%
confidence intervals (CIs). If a large number of different adverse
events are reported across the studies (for example, more than
five different adverse events), 99% CIs will be reported for this
outcome to account for multiplicity of statistical testing.
We will report change in seizure frequency as the mean differ-
ence (MD) in the change from baseline, with 95% CIs. We will
also report quality of life as MD, with 95% CIs, where the same
scales are used across studies. If different quality-of-life scales are
reported across studies, we will consider the similarity of the do-
mains and questions of the scales. If we deem the different scales to
be sufficiently similar, we will report pooled quality-of-life scores
as the standardised mean difference (SMD), with 95% CIs. If the
different scales are not deemed sufficiently similar to combine, we
will report each scale in separate analyses (where data allow), or in
a narrative review.
Unit of analysis issues
We will only include studies which randomise participants indi-
vidually (i.e. cluster-randomised trials will not be included). We
will include cross-over trials if each treatment period was a least
12 weeks in length and the trial had a suitable washout period.
If cross-over studies are included, we will use methods recom-
mended by Elbourne for pooling cross-over data, which take ac-
count of the correlation between measurements taken from the
same group of participants via paired analyses (Elbourne 2002).
If limited data are available, we will only be able to either use the
first-period data only, or to treat the cross-over studies as if they
are parallel studies, which is a conservative approach and will not
take account of within-patient correlation.
If trials with more than two treatment arms are identified (e.g.
drug A, drug B, and placebo), we will construct separate head-to-
head comparisons to consider the different pairs of interventions
and controls.
Dealing with missing data
We will record the attrition rates reported in each trial and, if
appropriate, we will attempt to contact the original trial authors if
the extent ofmissing data is unclear. In order to allow an intention-
to-treat analysis within this review, we will extract and report data
by randomised treatment groups where possible, irrespective of
compliance with allocated treatment, exclusion from analysis or
loss to follow-up.
In the event of substantial amounts of missing outcome data,
we will consider the potential bias that may have been intro-
duced when interpreting the results, particularly if missing data
are deemed to not be missing at random.
If appropriate for primary outcomes of seizure freedom and re-
sponder rate, we will consider sensitivity analyses such as best-case
scenario andworst-case scenario analyses (in the best-case scenario,
individuals in the treatment group are assumed to have a good
outcome and those in the control group are assumed to have a bad
outcome; in the worst-case scenario the opposite is assumed).
Assessment of heterogeneity
We will assess clinical heterogeneity by reviewing the differences
across trials in design, characteristics of recruited participants and
interventions. We will also estimate heterogeneity statistically us-
ing a Chi2 test for heterogeneity (with a conservative judgement of
P value less than 0.1 suggesting heterogeneity), and the I2 statistic.
We will interpret the I2 statistic as follows (Deeks 2011):
1. 0% to 40% might not be important;
2. 30% to 60% may represent moderate heterogeneity;
3. 50% to 90% may represent substantial heterogeneity;
4. 75% to 100%: considerable heterogeneity.
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Assessment of reporting biases
If a sufficient number of trials (10 or more) are included in any
comparison, we will investigate publication bias by using a funnel
plot and examining any asymmetry.
To assess selective reporting bias, we will compare the measure-
ments and outcomes planned by the original investigators during
the trial with those reported within the published paper, by check-
ing the trial protocols (when available) against the information in
the final publication. Where published protocols are not available
and trial authors do not provide an unpublished protocol on re-
quest, we will compare the ’Methods’ and the ’Results’ sections
of the published papers. We will also use our knowledge of the
clinical area to identify where trial investigators have not reported
commonly used outcome measures.
Data synthesis
If we deem that trials are sufficiently homogenous in design, partic-
ipant characteristics and interventions, wewill performmeta-anal-
ysis usingMantel-Haenzelmethodology for dichotomous data and
inverse variance methodology for continuous data (see Measures
of treatment effect). We intend to use a fixed-effect meta-analysis
model in the first instance. If substantial or considerable hetero-
geneity is found (i.e. an I2 value of more than 50%), we will repeat
the meta-analysis with a random-effects model and compare the
results of both models.
If we deem that the designs, participant characteristics and inter-
ventions are too heterogeneous to combine data, we will report
results in a narrative review. Where appropriate, we will present
outcome data in tables or enter trial-specific data into forest plots
for visual purposes, without pooling any outcome data.
Subgroup analysis and investigation of heterogeneity
Wewill assess clinical and statistical heterogeneity using the meth-
ods outlined in Assessment of heterogeneity.
If appropriate, and if data allow, we plan to conduct the following
subgroup analyses for all outcomes.
1. Type of epilepsy (focal versus generalised onset, and
temporal versus extratemporal onset)
2. Catamenial pattern (C1, C2, and C3)
3. Age groups, as defined by the trials (e.g. puberty, sexual
maturity, peri-menopausal)
Sensitivity analysis
As outlined in Dealing with missing data, if a substantial amount
of outcome data is missing, we will consider sensitivity analyses
such as best-case scenario and worst-case scenario analyses.
We will also consider, if appropriate, performing a sensitivity anal-
ysis excluding studies with a high risk of bias across any of the
domains outlined in Assessment of risk of bias in included studies.
Summary of findings and quality of the evidence
Wewill generate a ’Summary of findings’ table for each comparison
of the review, including all outcomes (Schünemann 2011): seizure
freedom, responder rate, change in seizure frequency, withdrawals,
adverse events, and quality of life.
For clarity and brevity in the tables, we will report a general state-
ment about the summary of findings for secondary outcomes
(withdrawals, adverse events, quality of life), based on different
reasons for withdrawal, different adverse events and different qual-
ity-of-life scales.
We will determine the quality of the evidence using the GRADE
approach (GRADE 2004), and downgrade evidence in the pres-
ence of a high risk of bias in at least one study, indirectness of
the evidence, unexplained heterogeneity or inconsistency, impre-
cision of results, and high probability of publication bias. We will
downgrade evidence by one level if we consider the limitation to
be serious, and by two levels if very serious.
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5. (menstrua$ adj4 epilep$).tw.
6. (menstrua$ adj4 seizure$).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. (randomized controlled trial or controlled clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 7 and 13
15. remove duplicates from 14
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